Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Biol Regul Homeost Agents ; 33(4): 1019-1022, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31347346

RESUMO

Mesenchymal stem cells (MSCs) are able to exert immunomodulatory and anti-inflammatory actions. Thanks to these properties, MSCs may be a promising alternative approach for the treatment of inflammatory disease. Important cytokines involved in inflammation are those included in the IL-1 family. Interleukin-37 (IL-37) is one of the member able to suppress both innate and adaptive immunity. Recently, it was found that MSCs and their derivatives can modulate IL-37, and MSCs expressing IL-37 seem to have an enhanced therapeutic efficacy.


Assuntos
Interleucina-1/fisiologia , Transplante de Células-Tronco Mesenquimais , Células-Tronco Mesenquimais/citologia , Citocinas , Humanos , Inflamação
2.
Curr Res Transl Med ; 65(2): 51-60, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28466824

RESUMO

Parkinson's disease is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, and as a consequence, by decreased dopamine levels in the striatum. Currently available therapies are not able to stop or reverse the progression of the disease. A novel therapeutic approach is based on cell therapy with stem cells, in order to replace degenerated neurons. Among stem cells, mesenchymal stem cells seemed the most promising thanks to their capacities to differentiate toward dopaminergic neurons and to release neurotrophic factors. Indeed, mesenchymal stem cells are able to produce different molecules with immunomodulatory, neuroprotective, angiogenic, chemotactic effects and that stimulate differentiation of resident stem cells. Mesenchymal stem cells were isolated for the first time from bone marrow, but can be collected also from adipose tissue, umbilical cord and other tissues. In this review, we focused our attention on mesenchymal stem cells derived from different sources and their application in Parkinson's disease animal models.

3.
J Affect Disord ; 177: 108-13, 2015 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-25766270

RESUMO

BACKGROUND: Major depressive disorder (MDD) and bipolar disorder (BD) are the two most common mood disorders. Given the recognized involvement of catecholamines in depression, genetic research focused on the evaluation of polymorphisms in genes coding for proteins that regulate neurotransmitter release, transport and degradation. Here we aimed at evaluating the distribution of two genetic variants of catechol-O-methyltransferase (COMT), namely the well characterized missense polymorphism G1947A (Val158Met) and the recently reported synonymous polymorphism C1886G (Leu136Leu), in MDD and BD patients compared with healthy subjects. METHODS: Genotyping for COMT polymorphisms was carried out by DNA direct sequencing in 112 patients (54 MDD and 58 BD) and 58 healthy subjects. RESULTS: We did not find significant differences in the Val158Met variant distribution between patients and controls. Instead, we found that the C1886 major allele and the CC1886 wild-type genotype frequencies were significantly higher in controls than in both groups of patients. On the contrary, the G1886 minor allele and the heterozygous CG1886 genotype were significantly more present in both MDD and BD patients than in healthy subjects. When looking at combined polymorphisms, we found a significantly higher frequency of the double heterozygous diplotype CG/GAVal/Met158 in both MDD and BD patients than in controls. Instead, the diplotype CC/GAVal/Met158 showed a significantly higher frequency in controls than in BD patients. LIMITATIONS: The small size of our study cohort may limit the generalizability of the present findings. CONCLUSIONS: This work first showed the association of combined Leu136Leu and Val158Met variants of COMT gene with MDD and BD.


Assuntos
Catecol O-Metiltransferase/genética , Transtornos do Humor/genética , Mutação de Sentido Incorreto/genética , Polimorfismo Genético/genética , Alelos , Análise de Variância , Transtorno Bipolar/genética , Transtorno Depressivo Maior/genética , Feminino , Humanos , Leucina , Masculino , Metionina , Pessoa de Meia-Idade , Valina
4.
Free Radic Res ; 49(3): 299-308, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25547897

RESUMO

Aberrant transglutaminase 2 (TG2) expression and protein cross-linking activity have been associated with several chronic neurodegenerative disorders in which inflammatory processes triggered by activated microglia and monocytes play a key role, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis. Interestingly, mild-to-moderate hyperhomocysteinemia (HHcy), corresponding to increased plasma homocysteine (Hcy) concentrations in the range 16-60 µM, have recently been associated with the above-cited diseases. Using THP-1 monocytes, here we investigated the role of TG2 in cell response to mildly elevated Hcy concentrations. A five-day incubation with Hcy (∼25 µM) increased reactive oxygen species, peroxide lipids, as well as 8-hydroxyguanosine levels by twofold, and decreased the endogenous cell antioxidant defenses, that is reduced glutathione, by 50% in Hcy-exposed cultures compared with controls (p < 0.01). Hcy-induced oxidative stress was associated with increases in TG2 expression and activity, as well as nuclear factor kappa B activation. Notably, the latter was reduced in the presence of the TG-specific inhibitor R283. Hcy exposure also significantly increased the mRNA levels of tumor necrosis factor alpha, interleukin (IL)-6, and IL-1ß, as well as the level of Hcy-inducible endoplasmic reticulum (ER) stress protein, a marker of ER stress, in Hcy-exposed cultures compared with controls. Notably, these effects were dramatically reduced by R283. These preliminary findings indicate that TG2 plays a key role in Hcy-induced activation of THP-1 monocytes, involving oxidative as well as ER stress and inflammation. This underlines the potential of TG2 inhibition in the therapeutic management of inflammatory processes contributing to neurodegenerative disorders associated with mild HHcy.


Assuntos
Proteínas de Ligação ao GTP/metabolismo , Homocisteína/farmacologia , Monócitos/enzimologia , Transglutaminases/metabolismo , Antioxidantes/metabolismo , Linhagem Celular , Citocinas/genética , Estresse do Retículo Endoplasmático , Proteínas de Ligação ao GTP/genética , Humanos , Monócitos/imunologia , NF-kappa B/metabolismo , Estresse Oxidativo , Proteína 2 Glutamina gama-Glutamiltransferase , Transglutaminases/genética , Regulação para Cima
5.
Neurochem Res ; 39(8): 1485-95, 2014 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-24867323

RESUMO

Epidemiological and experimental evidence indicated that hyperhomocysteinemia is associated with neurodegeneration. However, homocysteine neurotoxic effects have been so far investigated mostly by employing homocysteine concentrations (≥100 µM) much higher than homocysteine mean plasma levels (20 µM) observed in patients with neurodegenerative disorders. While evaluating the effects of a prolonged exposure to ~20 µM homocysteine in neuronal-like differentiated SH-SY5Y cells, we observed a 35% loss of cell viability and a four-fold increase in reactive oxygen species levels in cells incubated with homocysteine for five days compared with controls. Moreover, homocysteine increased by 30% and around two-fold, respectively, the Comet-positive cell number and DNA damage indexes (tail length, T-DNA, olive tail moment) compared with controls. Cell response to homocysteine-induced DNA damage involved the up-regulation of Bax and, at a greater extent, Bcl-2, but not caspase-3, in association with a p53-independent increase of p21 levels; concomitantly, also p16 levels were increased. When looking at time-dependent changes in cyclin expression, we found that a significant up-regulation of cyclins D1, A1, E1, but not B1, concomitant with p21 down-regulation, occurred in cells incubated with homocysteine for three days. However, in line with the observed increase of p21 and p16 levels, a five days incubation with homocysteine induced cyclin down-regulation accompanied by a strong reduction of phosphorylated pRB amounts. These results suggest that, when prolonged, the exposure of neuronal-like cells to mildly elevated homocysteine concentrations triggers oxidative and genotoxic stress involving an early induction of cyclins, that is late repressed by G1-S check-point regulators.


Assuntos
Sobrevivência Celular/efeitos dos fármacos , Sobrevivência Celular/fisiologia , Homocisteína/toxicidade , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Linhagem Celular Tumoral , Relação Dose-Resposta a Droga , Humanos , RNA Mensageiro/biossíntese
6.
Thromb Haemost ; 70(2): 241-3, 1993 Aug 02.
Artigo em Inglês | MEDLINE | ID: mdl-8236126

RESUMO

In order to evaluate the effects of hypocholesterolemic drugs on plasma fibrinogen concentration, six groups of subjects with primary hypercholesterolemia have been put on treatment with diet alone or diet plus fenofibrate (100 mg t.i.d.), slow release bezafibrate (400 mg once a day), gemfibrozil (600 mg b.i.d.), simvastatin (20 mg once a day) or pravastatin (20 mg once a day) respectively. After 1 month of therapy, plasma fibrinogen significantly decreased by 9% and 15% in fenofibrate and bezafibrate groups respectively and increased by 19% in gemfibrozil treated patients. After 4 months of therapy the changes were -16% with fenofibrate, -10% with bezafibrate and +20% with gemfibrozil. No significant changes were observed in patients treated with diet alone, simvastatin or pravastatin. The fibrinogen lowering effect of fenofibrate and bezafibrate does not seem to be related to the hypolipidemic activity of the drugs.


Assuntos
Bezafibrato/farmacologia , Fenofibrato/farmacologia , Fibrinogênio/análise , Genfibrozila/farmacologia , Inibidores de Hidroximetilglutaril-CoA Redutases , Hiperlipoproteinemia Tipo II/sangue , Lovastatina/análogos & derivados , Pravastatina/farmacologia , Adulto , Idoso , Bezafibrato/uso terapêutico , Colesterol na Dieta/administração & dosagem , Terapia Combinada , Feminino , Fenofibrato/uso terapêutico , Genfibrozila/uso terapêutico , Humanos , Hiperlipoproteinemia Tipo II/dietoterapia , Hiperlipoproteinemia Tipo II/tratamento farmacológico , Lipídeos/sangue , Lovastatina/farmacologia , Lovastatina/uso terapêutico , Masculino , Pessoa de Meia-Idade , Pravastatina/uso terapêutico , Sinvastatina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...